

Appendix: Patient Group Industry / Grant Sponsorship Summary

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

No help (financial or in-kind) was received from outside sources to develop, complete and summarize our submission.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

No help (financial or in-kind) was received from outside sources to develop, complete and summarize our submission.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
Sanofi
Janssen
Celgene
The binding Site
AbbVie
Amgen
Novartis
BMS
Onyx
Merck
Takeda
Karyopharm
Otsuka

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Martine Elias

Position: Executive Director

Patient Group: Myeloma Canada

Date: March 28 2019